Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fotagliptin in Renal Insufficiency
NCT06883656Phase 1Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fotagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Pharmacokinetic characteristics at 8 days. Started Mar 2022; status: completed.
02
Drugs
fotagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06883656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06883656.